Biolevate Raises €30M Series A

Biolevate, based in Paris, France, provides an enterprise agentic AI platform that automates scientific and regulatory workflows for the life sciences industry. The company has raised €30 million in Series A funding to support its international expansion and enhance its product capabilities.

Investors

The round was co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund (MGHIF), Station F, and existing investor EQT Ventures.

Biolevate Use of Funds

Biolevate plans to use the new capital to accelerate its international expansion, deepen its product capabilities, and scale its platform deployments with life sciences organizations globally.

About Biolevate

Biolevate develops an enterprise agentic AI platform designed to automate scientific and regulatory workflows. Its platform transforms scientific and regulatory knowledge into auditable workflows grounded in source evidence, enabling organizations to use AI in regulated environments while maintaining human oversight.

Funding Details

Company Website: https://biolevate.com

Company: Biolevate
Raised: €30M
Round: Series A
Funding Date: September 22, 2026
Lead Investor: RAISE France, Orange Ventures
Additional Investors: MSD Global Health Innovation Fund (MGHIF), Station F, EQT Ventures
Software Category: Life Sciences AI
Source: https://tech.eu/2026/09/22/biolevate-lands-eur30m-series-a-to-scale-life-sciences-ai/